EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Seizures associated with clozapine augmentation by other antipsychotics: a pharmacovigilance–pharmacodynamic analysis using VigiBase

Masakazu Hatano iD, Hirofumi Hamano, Masaya Kanda, Takenao Koseki, Tsuyoshi Nakai, Rina Horii, Nozomi Yoshihara, Takeo Saito, Kenshi Takechi, Satoru Esumi, Yoshito Zamami, Shigeki Yamada

Therapeutic Advances in Psychopharmacology · 2026-07 · 16

DOI: 10.1177/20451253261472920 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Advances in Psychopharmacology, online erschienen am 30.07.2026. Verfasst von Masakazu Hatano und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacotherapeutics and Informatics, Fujita Health University School of Medicine, 1-98 Dengakugakubo, Kutsukake, Toyoake 470-1192, Jap…. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: The Research Foundation for Pharmaceutical Sciences, Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Clozapine is associated with a high risk of central nervous system abnormalities. However, seizure risk related to interactions between clozapine and other antipsychotics remains poorly characterized, and the pharmacological mechanisms underlying these seizures are unclear.

Objectives

We aimed to evaluate safety signals for seizures associated with clozapine augmentation by other antipsychotics and analyze the relationship between these signals and neurotransmitter receptor occupancy profiles.

Design

A pharmacovigilance–pharmacodynamic analysis using a spontaneous reporting system.

Methods

This pharmacovigilance study used VigiBase, an adverse drug reaction database maintained by the World Health Organization. Drug–drug interactions (DDIs) between clozapine and other antipsychotics were assessed using the Ω shrinkage measure model. The association between DDI signals and neurotransmitter receptor occupancy was evaluated using linear regression. Robustness was tested using four frequency statistical models: additive, multiplicative, combination risk ratio, and chi-square statistic models.

Results

Of 38,758,077 reports in VigiBase between 1990 and 2024, 230,371 involved clozapine. Among antipsychotics classified under ATC code N05A, DDIs with clozapine were detected for amisulpride, chlorpromazine, haloperidol, lurasidone, olanzapine, penfluridol, risperidone, sulpiride, zotepine, and zuclopenthixol. A significant association between dopamine D 4 receptor occupancy and the point estimates of signal values was observed in the Ω shrinkage measure model (β = 0.295, 95% confidence interval: 0.119–0.471, p = 0.002) and replicated across all frequency statistical models.

Conclusions

These findings suggest a potential role of dopamine D 4 receptor occupancy in seizures associated with clozapine augmentation by other antipsychotics. Further large-scale epidemiological studies are needed to validate these findings.

Schlagwörter

Stichwörter der Autor:innen

adverse drug reaction reporting systemsdopamine D4dopamine antagonistsdrug interactionsreceptorsschizophrenia

Autor:innen und Institutionen

  • Department of Pharmacotherapeutics and Informatics, Fujita Health University School of Medicine, 1-98 Dengakugakubo, Kutsukake, Toyoake 470-1192, Japan.
  • Department of Pharmacy, Okayama University Hospital, Okayama, Japan.
  • Department of Pharmacy, Asahikawa Medical University Hospital, Asahikawa, Japan.
  • Department of Pharmacotherapeutics and Informatics, Fujita Health University School of Medicine, Toyoake, Japan.
  • Department of Advanced Medical Professional Development, Fujita Health University Graduate School of Medical Sciences, Toyoake, Japan.
  • Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Japan.

ORCID-Profile: Masakazu Hatano

Förderung

  • The Research Foundation for Pharmaceutical Sciences
  • Japan Society for the Promotion of Science

Zitieren

APA

Hatano, M., Hamano, H., Kanda, M., Koseki, T., Nakai, T., Horii, R., Yoshihara, N., Saito, T., Takechi, K., Esumi, S., Zamami, Y., & Yamada, S. (2026). Seizures associated with clozapine augmentation by other antipsychotics: a pharmacovigilance–pharmacodynamic analysis using VigiBase. Therapeutic Advances in Psychopharmacology, 16. https://doi.org/10.1177/20451253261472920

Vancouver

Hatano M, Hamano H, Kanda M, Koseki T, Nakai T, Horii R, et al. Seizures associated with clozapine augmentation by other antipsychotics: a pharmacovigilance–pharmacodynamic analysis using VigiBase. Therapeutic Advances in Psychopharmacology. 2026;16. doi:10.1177/20451253261472920

BibTeX
@article{Hatano2026,
  author = {Hatano, Masakazu and Hamano, Hirofumi and Kanda, Masaya and Koseki, Takenao and Nakai, Tsuyoshi and Horii, Rina and Yoshihara, Nozomi and Saito, Takeo and Takechi, Kenshi and Esumi, Satoru and Zamami, Yoshito and Yamada, Shigeki},
  title = {Seizures associated with clozapine augmentation by other antipsychotics: a pharmacovigilance–pharmacodynamic analysis using VigiBase},
  journal = {Therapeutic Advances in Psychopharmacology},
  year = {2026},
  volume = {16},
  doi = {10.1177/20451253261472920}
}
Kostenlos starten →